Breaking News

Financial Reports: Gilead

By Gil Roth | February 5, 2014

Stribild, Complera/Eviplera drive growth

Gilead 4Q13

4Q Revenues: $3.1 billion (+21%)

4Q Earnings: $791 million (+4%)

FY Revenues: $11.2 billion (+15%)

FY Earnings: $3.1 billion (+19%)

Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead's cardiovascular franchise posted 24% gains in FY, with Letairis posting $520 million in sales (+27%) and Ranexa adding $449 million (+20%).

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • CMOs: A Flexibility Alternative

    CMOs: A Flexibility Alternative

    Philip K. Burns, CRO-Consulting||January 28, 2016
    A look at how to include CMOs as an option to improve overall flexibility